Ex­clu­sive: As­pen Neu­ro­science col­lects large Se­ries B to com­pete against Bay­er's Parkin­son's cell ther­a­py

Damien McDe­vitt thinks fre­quent­ly about the name As­pen Neu­ro­science. Specif­i­cal­ly, should the neu­ro­science por­tion be dropped as the San Diego biotech con­sid­ers ex­pand­ing be­yond the CNS?

McDe­vitt, the 21-year Glax­o­SmithK­line vet­er­an and for­mer Akcea Ther­a­peu­tics CEO who took over the helm of As­pen in Jan­u­ary 2021, now has even more deep-pock­et­ed in­vestors to help him and his 60-plus em­ploy­ee team con­sid­er their voy­age be­yond Parkin­son’s thanks to a $147.5 mil­lion Se­ries B.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER